BIOTECH & PHARMA

    Biotech and pharma stocks listed on the ASX.

    Visioneering Technologies ASX VTI eyes US myopia market FDA approval CooperVision MiSight contact lens NaturalVue

    Visioneering Technologies eyes US myopia market after FDA approval for industry peer

    Alcidion Group ASX ALC mobile electronic medical record Miya MEMRe

    Alcidion launches medical mobile app to improve delivery and safety of patient care

    Prescient Therapeutics ASX PTX Carina Biotech Chimeric Antigen Receptor T-cell cancer solid tumour

    Prescient Therapeutics and Carina Biotech to develop CAR-T cell solid tumour therapies

    ECS Botanics ASX manufacturing licence tasmania medicinal cannabis

    ECS Botanics granted manufacturing licence for medicinal cannabis facility

    Orthocell ASX OCC patent CelGro collagen rope anterior cruciate ligament

    Orthocell receives patent for breakthrough CelGro ‘collagen rope’ to treat ACL injuries

    THC Global ASX medicinal cannabis Southport facility Office of Drug Control

    THC Global to begin cannabis production at Southport facility following ODC permit

    Nanoveu ASX NVU EyeFyx lens correcting digital phone tablet

    Nanoveu’s third generation vision correcting smartphone and tablet lenses surpass previous versions

    Bionomics ASX BNO fast track treatment post-traumatic stress disorder PTSD

    Bionomics on fast track to developing a treatment for post-traumatic stress disorder

    Impression Healthcare ASX IHL John Michailidis Incannex cannabinoid pharmaceutical

    Impression Healthcare recruits Big Pharma executive to complete cannabinoid drug discovery goal

    Invion IVX ASX Peter MacCallum Cancer Centre penile anal cancer

    Invion and Peter MacCallum Cancer Centre to trial photodynamic therapy on penile and anal cancers

    Suda Pharmaceuticals ASX SUD Oromist technology Oral spray medicinal cannabis formula

    SUDA Pharmaceuticals inks deal with Cann Pharmaceutical to develop medical cannabis oral spray

    THC Global ASX Southport manufacturing medicinal cannabis

    THC Global reports revenue in NZ and Canada, sets stage for Australian production

    Paradigm Biopharmaceuticals ASX PAR regulatory progress iPPS Zilosul

    Regulatory progress means Paradigm Biopharmaceuticals will treat ex-NFL players with Zilosul later this year

    Immunge ASX IMU US Department Defense City Hope gastric cancer

    Researchers to study Imugene’s cancer therapy following US Department of Defense grant

    Noxopharm ASX NOX anti-cancer effect DARRT prostate brain

    Noxopharm confirms durable anti-cancer effect from lead drug Veyonda

    Mesoblast ASX MSB manufacturing agreement Lonza allogeneic cell therapy

    Mesoblast signs manufacturing agreement with Lonza, prepares for US launch

    Neuren Pharmaceuticals ASX NEU FDA grants orphan drug designation Phelan-McDermid Pitt Hopkins syndrome

    Neuren Pharma granted orphan drug status for treatment of Phelan-McDermid, Pitt Hopkins and Angelman syndromes

    Immutep ASX IMM TACTI-mel Melanoma tumour shrinkage Phase I clinical study Keytruda metastatic melanoma

    Positive safety data reported from Immutep’s clinical trial to treat metastatic melanoma

    Admedus ASX AHZ sell CardioCel VascuCel patch LeMaitre Vascular

    Admedus agrees to sell CardioCel and VascuCel patch business to LeMaitre Vascular

    Dimerix ASX DXB DMX-700 Chronic Obstructive Pulmonary Disease COPD drug pipeline

    Dimerix targets ‘important new drug discovery’ in the treatment of chronic obstructive pulmonary disease

    Phylogica ASX PYC Therapeutics human retina in a dish model drug childhood blindness

    Phylogica achieves milestone in drug study aimed at treating childhood blindness

    Load more
    Small Caps ASX Australian stock market
    Small Caps is Australia's #1 site for market news & information on ASX listed small cap companies.

    Small Caps and affiliated companies accept no responsibility for any claim, loss or damage as a result of information provided or its accuracy. The information provided on this site is general in nature, not financial product advice, see a financial expert before making any investment decision. Your personal objectives, financial situation or needs have not been taken into consideration. There may be a conflict of interest present with commercial arrangements with companies and/or stock held. Small Caps or an associate may receive a commission for funds raised.
    Copyright 2019 Small Caps. All rights reserved.